Some patients find their maintenance dose is only one step below their therapeutic dose
Together, these factors can make bowel movements less frequent and more difficult
But a newer drug called retatrutide is generating real excitement in the medical community, and for good reason
How Retatrutide Compares to Current GLP1 and DualAgonist Drugs Current injectable weightloss drugs can be grouped roughly as: GLP1 single agonists semaglutide (Ozempic, Wegovy), liraglutide, etc
By activating GLP-1 receptors, retatrutide is thought to enhance insulin secretion in a glucose-dependent manner, suppress glucagon release, and slow gastric emptying effects that may contribute to improved blood glucose control and reduced appetite
Those consistently drinking 70 or more ounces daily had zero serious complications